Primary membranous nephropathy: an endless story

Area of Science:

• Nephrology
• Immunology
• Autoimmune Diseases

Background:

• Primary membranous nephropathy (PMN) is an autoimmune disorder targeting podocyte antigens, leading to immune complex formation.
• While often idiopathic, PMN can be secondary to infections, systemic diseases, drugs, or malignancy, complicating diagnosis.
• The disease course is variable, with a significant risk of progression to end-stage renal disease (ESRD) or cardiovascular events.

Purpose of the Study:

• To review the current understanding of primary membranous nephropathy (PMN) etiology and pathogenesis.
• To discuss diagnostic challenges in differentiating primary from secondary forms of the disease.
• To outline current treatment strategies and highlight the need for further research.

Main Methods:

• Literature review of primary membranous nephropathy (PMN).
• Analysis of current diagnostic criteria and challenges.
• Evaluation of existing treatment modalities and their outcomes.

Main Results:

• PMN pathogenesis involves autoantibodies against podocyte antigens, but etiology remains unclear.
• Distinguishing PMN from secondary causes can be challenging, especially when symptoms are delayed.
• Current treatments include supportive care for asymptomatic proteinuria and immunosuppression for nephrotic syndrome, with therapies like rituximab and calcineurin inhibitors showing promise but with potential for relapse.

Conclusions:

• Primary membranous nephropathy (PMN) requires effective treatment strategies to prevent progression to ESRD.
• Optimizing immunosuppressive regimens and supportive care is crucial.
• High-quality randomized controlled trials are essential to determine the most effective treatments with the best therapeutic index.